Source-grounded facts extracted from Citius Pharmaceuticals, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Citius Pharmaceuticals, Inc. reported fiscal second quarter ended March 31, 2026 results: revenue Net product revenues of $1.7 million for the three months ended March 31, 2026.
“Net product revenues of $1.7 million for the three months ended March 31, 2026”
Citius Pharmaceuticals, Inc. amended Third Amendment to Promissory Note with Citius Oncology, Inc. (effective 2026-05-04).
“the Company and Citius Oncology entered into a Third Amendment to Promissory Note (the “Third Amendment”), which amends the promissory note, dated August 16, 2024, as previously amended on September 10, 2025 and December 10, 2025, issued by the Citius Oncology to the Company in the original principal amount of $3,800,111 (the “Promissory Note”)”
Citius Pharmaceuticals, Inc. entered into Purchase Agreement with certain institutional investors valued at approximately $5.0 million (effective 2026-04-23).
“On April 23, 2026, Citius Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors for the issuance and sale, in a registered direct offering by the Company (the “Offering”), of 4,730,457 shares of the Company’s common stock, par value $0.001 per share (the “Shares”), and pre-funded warrants to purchase up to 345,686 shares of common stock (the “Pre-funded Warrants”) at an offering price of $0.985 and $0.9849, respectively.”
Citius Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“February 9, 2026, Nasdaq Stock Market LLC (“Nasdaq”) notified the Company that for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days, or until August 10, 2026, to regain compliance with the Bid Price Rule. If at any time before August 10, 2026, the bid price of the Company's co”
Citius Pharmaceuticals, Inc.: Increased authorized shares from 26,000,000 to 260,000,000 and authorized common shares from 16,000,000 to 250,000,000 (effective 2025-06-09).
“On June 9, 2025, the Company filed a Certificate of Amendment to its Articles of Incorporation with the Secretary of State of the State of Nevada to increase the authorized shares from 26,000,000 to 260,000,000 and increase the authorized common shares, par value $0.001 per share, from 16,000,000 to 250,000,000 (the “Amendment”).”
Citius Pharmaceuticals, Inc. incurred loan of $1 million with PAGODA RESOURCES, INC at 15.00% per year, compounded monthly maturing December 2, 2025.
“On June 2, 2025, Citius Pharmaceuticals, Inc. (the “Company”) issued an unsecured promissory note for an aggregate principal amount of $1 million (the “Note”) to PAGODA RESOURCES, INC, a Pennsylvania corporation.”
Citius Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(iv), 5810(c)(3)(A)).
“May 29, 2025, Citius Pharmaceuticals, Inc. (the “Company”) received a determination letter (the “Letter”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market notifying the Company that, based upon the closing bid price of the Company’s common stock for the prior 33 consecutive business days, the Company was not in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2). The Letter states that, pursuant to Nasdaq Listing Rule 5810(c)(3)(A)”
Citius Pharmaceuticals, Inc.: Filed Certificate of Designation for Series A Preferred Stock with specific voting, redemption, and non-economic terms (effective 2025-04-17).
“On April 17, 2025, the Company filed a certificate of designation (the “Certificate of Designation”) with the Nevada Secretary of State, effective as of the time of filing, designating the powers, rights, privileges and restrictions of the shares of Series A Preferred Stock.”
Citius Pharmaceuticals, Inc.: Reduced quorum requirement for stockholder meetings from majority to at least one-third of voting power (effective 2025-04-16).
“As of April 16, 2025, the Board approved the amendment of the Company’s Amended and Restated Bylaws, effective as of April 16, 2025 (the “Bylaws Amendment”), to reduce the quorum required for the transaction of business at stockholder meetings from the holders of at least a majority of the voting power of the Company’s outstanding shares of capital stock to the holders of at least one-third (1/3) of the voting power of the Company’s outstanding shares of capital stock.”
Citius Pharmaceuticals, Inc.: Effected a 1-for-25 reverse stock split of common stock and decreased authorized shares from 400,000,000 to 16,000,000 (effective 2024-11-25).
“Citius Pharmaceuticals, Inc. (the “Company”) filed a Certificate of Change (the “Certificate of Change”) with the Secretary of State of the State of Nevada to (i) effect a 1-for-25 reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding shares of common stock, par value $0.001 per share (the “Common Stock”), and (ii) decrease the number of total authorized shares of Common Stock from 400,000,000 shares to 16,000,000 shares. The Reverse Stock Split is intended for the Company to regain compliance with the minimum bid price requirement of $1.00 per share of common stock for continued listing on the Nasdaq Capital Market. The Reverse Stock Split became effective at 5:00 p.m., Eastern Time, on November 25, 2024”
Citius Pharmaceuticals, Inc. reported fiscal second quarter 2024 ended March 31, 2024 results: net income Net loss was $8.5 million and $17.8 million, or ($0.05) and ($0.11) per share for the three and six months ended March 3, EPS ($0.05) and ($0.11) per share for the three and six months ended March 31, 2024.
“Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update”
Citius Pharmaceuticals, Inc. entered into Purchase Agreement with certain institutional investors (effective 2024-04-25).
“On April 25, 2024, Citius Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors for the issuance and sale, in a registered direct offering by the Company (the “Offering”), of 21,428,574 shares of the Company’s common stock, par value $0.001 per share (the “Shares”) and warrants (the “Warrants”) to purchase up to 21,428,574 shares of common stock.”
Citius Pharmaceuticals, Inc. shareholders approved Ratification of Wolf & Company, P.C. as independent registered public accounting firm for fiscal year ending September 30, 2024 at the 2024-03-12 meeting.
“Also at the meeting, our stockholders ratified the selection of Wolf & Company, P.C. as our independent registered public accounting firm for the fiscal year ending September 30, 2024. The vote for such approval was 77,204,591 shares for, 2,548,248 shares against, 5,613,605 shares abstaining, and no broker non-votes.”
Citius Pharmaceuticals, Inc. shareholders approved Election of seven directors for a one-year term at the 2024-03-12 meeting.
“We held our 2024 annual meeting of stockholders on March 12, 2024. At the meeting, stockholders elected the following seven members to our Board of Directors for a one-year term expiring at the annual meeting of stockholders to be held in 2025 or until their successors are duly elected and qualified, based on the following votes: Nominee For Withheld Broker Non-Votes Leonard Mazur 33,233,815 3,936,260 48,196,369 Myron Holubiak 33,776,316 3,393,759 48,196,369 Suren Dutia 33,496,184 3,673,891 48,196,369 Dr. Eugene Holuka 31,416,676 5,753,399 48,196,369 Dennis M. McGrath 29,156,167 8,013,908 48,196,369 Robert Smith 34,234,323 2,935,752 48,196,369 Carol Webb 33,187,520 3,982,555 48,196,369”
Citius Pharmaceuticals, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
“March 12, 2024, Citius Pharmaceuticals, Inc. (the “Company”) received formal notice that the Nasdaq Stock Market LLC (“Nasdaq”) granted our request for an extension through September 9, 2024 (the “Extension Notice”) to evidence compliance with the $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). If at any time before September 9, 2024, the bid price of our common stock closes at $1.00 per share or more for a minimum of ten consecutive business days, Nasdaq will provide the Company with written co”
Citius Pharmaceuticals, Inc. reported first quarter of fiscal 2024 results: net income $9.2 million, or ($0.06) per share, EPS ($0.06) per share.
“On February 14, 2024, we issued a press release announcing our results of operations for the first quarter of fiscal 2024.”
Citius Pharmaceuticals, Inc. reported fiscal full year ended September 30, 2023 results: net income Net loss was $32.5 million, or ($0.22) per share, EPS ($0.22) per share.
“Net loss was $32.5 million, or ($0.22) per share for the full year ended September 30, 2023”
Citius Pharmaceuticals, Inc. entered into Merger Agreement with TenX Keane Acquisition (effective 2023-10-23).
“On October 23, 2023, Citius Pharmaceuticals, Inc. (“Citius Pharma”) and Citius Oncology, Inc. (“SpinCo”), a wholly owned subsidiary of Citius Pharma, entered into an agreement and plan of merger and reorganization (the “Merger Agreement”) with TenX Keane Acquisition, a Cayman Islands exempted company (“TenX”), and TenX Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of TenX (“Merger Sub”).”
Citius Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“September 12, 2023, Nasdaq Stock Market LLC (“Nasdaq”) notified Citius Pharmaceuticals, Inc. (the “Company”) that for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days, or until March 11, 2024, to regain compliance with the Bid Price Rule. If at any time before March 11, 2024”
Citius Pharmaceuticals, Inc. reported the fiscal third quarter ended June 30, 2023 results: net income Net loss was $8.5 million, or ($0.06) per share for the three months ended June 30, 2023.
“Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2023 Financial Results and Provides Business Update”
Citius Pharmaceuticals, Inc. reported the fiscal second quarter ended March 31, 2023 results: net income Net loss was $10.5 million and $14.1 million, or ($0.07) and ($0.10) per share for the three and six months ended March, EPS ($0.07) and ($0.10) per share.
“r ($0.07) and ($0.10) per share for the three and six months ended March 31, 2023, respectively, compared to a net loss of $7.6 million”
Citius Pharmaceuticals, Inc. entered into Purchase Agreement with certain institutional investors valued at combined offering price of $1.20 (effective 2023-05-03).
“On May 3, 2023, Citius Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors for the issuance and sale, in a registered direct offering by the Company (the “Offering”), of 12,500,001 shares of the Company’s common stock, par value $0.001 per share (the “Shares”) and warrants (the “Warrants”) to purchase up to 12,500,001 shares of common stock.”
Citius Pharmaceuticals, Inc. reported the fiscal first quarter ended December 31, 2022 results: net income Net loss was $3.6 million, or ($0.02) per share, EPS $0.02.
“On February 10, 2023, we issued a press release announcing our results of operations for the first quarter of fiscal 2023.”
Citius Pharmaceuticals, Inc. shareholders approved Ratification of Wolf & Company, P.C. as independent registered public accounting firm for fiscal year ending September 30, 2023 at the 2023-02-07 meeting.
“Finally, at the meeting, our stockholders ratified the selection of Wolf & Company, P.C. as our independent registered public accounting firm for the fiscal year ending September 30, 2023. The vote for such approval was 73,110,304 shares for, 1,546,136 shares against, 1,071,053 shares abstaining, and no broker non-votes.”
Citius Pharmaceuticals, Inc. shareholders approved Approval of the Citius Pharmaceuticals, Inc. 2023 Omnibus Stock Incentive Plan at the 2023-02-07 meeting.
“Next, at the meeting, our stockholders approved the Citius Pharmaceuticals, Inc. 2023 Omnibus Stock Incentive Plan. The vote for such approval was 22,065,354 shares for, 6,944,243 shares against, 780,696 shares abstaining, and 45,937,200 broker non-votes.”
Citius Pharmaceuticals, Inc. shareholders approved Election of seven directors for a one-year term at the 2023-02-07 meeting.
“We held our 2023 annual meeting of stockholders on February 7, 2023. At the meeting, stockholders elected the following seven members to our Board of Directors for a one-year term expiring at the annual meeting of stockholders to be held in 2024 and until their successors are duly elected and qualified, based on the following votes: Nominee For Withheld Broker Non-Votes Myron Holubiak 27,833,866 1,956,427 45,937,200 Leonard Mazur 27,708,003 2,082,290 45,937,200 Suren Dutia 27,404,373 2,385,920 45,937,200 Carol Webb 27,206,268 2,584,025 45,937,200 Howard Safir 27,493,869 2,296,424 45,937,200 Dr. Eugene Holuka 27,093,439 2,696,854 45,937,200 Dennis M. McGrath 27,486,435 2,303,858 45,937,200”
Citius Pharmaceuticals, Inc. reported the fiscal full year ended September 30, 2022 results: net income $33.6 million, EPS ($0.23) per share.
“Net loss was $33.6 million, or ($0.23) per share for the full year ended September 30, 2022 compared to a net loss of $23.1 million, or ($0.23) per share for the full year ended September 30, 2021.”
Jaime Bartushak changed role as Chief Financial Officer and Chief Business Officer at Citius Pharmaceuticals, Inc..
“Chief Financial Officer Jaime Bartushak will assume additional responsibilities as Chief Business Officer.”
Leonard Mazur was named as Chief Executive Officer and Chairman at Citius Pharmaceuticals, Inc..
“Leonard Mazur, Citius co-founder and Executive Chairman, has been named as Chief Executive Officer and Chairman.”
Myron Holubiak was appointed as Executive Vice Chairman at Citius Pharmaceuticals, Inc..
“the Board appointed Myron Holubiak, the current Chief Executive Officer, to the newly created position of Executive Vice Chairman”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.